Payment overview · 2025
General Payments
$54.56
3 reported records · 3 companies
Healthcare provider profile · identity verified
Justin Turner
Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, TN · NPI 1235670647
Verified facts
What the public records show
CMS Open Payments records show Justin Turner received $54.56 in general payments during 2025 across 3 reported records.
Fresenius Kabi USA, LLC accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $23.45 | 43.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.58 | 28.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.53 | 28.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $54.56 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 656 | 40 |
| Furosemide | Furosemide | 455 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 385 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 384 | 25 |
| Carvedilol | Carvedilol | 304 | 18 |
| Sertraline Hcl | Sertraline Hcl | 284 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 20 |
| Eliquis | Apixaban | 272 | 24 |
| Trazodone Hcl | Trazodone Hcl | 272 | 19 |
| Lisinopril | Lisinopril | 266 | 20 |
| Omeprazole | Omeprazole | 261 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 241 | 15 |
| Memantine Hcl | Memantine Hcl | 221 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 221 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 210 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 210 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 188 | 14 |
| Mirtazapine | Mirtazapine | 172 | 16 |
| Midodrine Hcl | Midodrine Hcl | 159 | 14 |
| Divalproex Sodium | Divalproex Sodium | 153 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 151 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | suppressed |
| Potassium Chloride | Potassium Chloride | 148 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | suppressed |
| Olanzapine | Olanzapine | 132 | suppressed |
| Famotidine | Famotidine | 130 | 14 |
| Metformin Hcl | Metformin Hcl | 124 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 115 | suppressed |
| Losartan Potassium | Losartan Potassium | 107 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 107 | suppressed |
| Levetiracetam | Levetiracetam | 106 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 11 |
| Sucralfate | Sucralfate | 86 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 68 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 66 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 62 | suppressed |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 57 | suppressed |
| Folic Acid | Folic Acid | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 52 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 52 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 52 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Prednisone | Prednisone | 46 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | suppressed |
| Lansoprazole | Lansoprazole | 45 | 12 |
| Hydrocortisone | Hydrocortisone | 39 | 12 |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 23 |
| Calcium Acetate | Calcium Acetate | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Epogen | Epoetin Alfa | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Steglatro | Ertugliflozin Pidolate | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 12 |
| Sevelamer Hcl | Sevelamer Hcl | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paliperidone Er | Paliperidone | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Nateglinide | Nateglinide | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | 11 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Matzim La | Diltiazem Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Permethrin | Permethrin | 12 | 12 |
| Scopolamine | Scopolamine | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54.56 · 3 records | Fresenius Kabi USA, LLC | DALVANCE, REXULTI, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error